Close Menu

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Wednesday that its revenues in the second quarter of 2009 were down 12 percent compared with the 2008 period, and it saw a profit swing to a loss.

The Omaha, Neb.-based genetic test provider said that it brought in revenues of $5.5 million for the three-month period ended June 30, compared with $6.2 million a year ago.

Transgenomic posted a loss of $730,000, or $.01 per share, compared to a net profit of $101,000, or $.00 per share, in the second quarter of 2008.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.